FDA calls meeting about Eli Lilly's Alzheimer's treatment
The agency has questions about brain bleeding and swelling potentially associated with donanemab, but is generally positive about the drug. The approval decision has been postponed twice.
The US Food and Drug Administration (FDA) is preparing to discuss its concerns about Eli Lilly’s experimental Alzheimer’s treatment donanemab ahead of an advisory committee meeting on the treatment on Monday, Endpoints reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Otsuka drops Alzheimer's agitation candidate
For subscribers
Eli Lilly to invest USD 5.3bn in obesity drug production
For subscribers
